Beyond unfractionated heparin and warfarin: current and future advances

MeSH terms

• Angina, Unstable / drug therapy
• Anticoagulants / adverse effects
• Anticoagulants / classification
• Anticoagulants / pharmacokinetics
• Anticoagulants / therapeutic use*
• Azetidines / adverse effects
• Azetidines / pharmacokinetics
• Azetidines / therapeutic use
• Benzimidazoles / adverse effects
• Benzimidazoles / therapeutic use
• Benzylamines / adverse effects
• Benzylamines / pharmacokinetics
• Benzylamines / therapeutic use
• Brain Ischemia / drug therapy
• Clinical Trials as Topic
• Coumarins / therapeutic use
• Dabigatran
• Factor Xa Inhibitors
• Fibrinolytic Agents / adverse effects
• Fibrinolytic Agents / classification
• Fibrinolytic Agents / pharmacokinetics
• Fibrinolytic Agents / therapeutic use
• Fondaparinux
• Forecasting
• Hemorrhage / chemically induced
• Heparin / therapeutic use
• Heparin, Low-Molecular-Weight / therapeutic use
• Hirudins / pharmacokinetics
• Humans
• Morpholines / pharmacokinetics
• Morpholines / therapeutic use
• Myocardial Infarction / drug therapy
• Peptide Fragments / pharmacokinetics
• Peptide Fragments / therapeutic use
• Polysaccharides / pharmacology
• Polysaccharides / therapeutic use
• Prothrombin / antagonists & inhibitors
• Pyrazoles / therapeutic use
• Pyridines / adverse effects
• Pyridines / therapeutic use
• Pyridones / therapeutic use
• Recombinant Proteins / pharmacokinetics
• Recombinant Proteins / therapeutic use
• Rivaroxaban
• Thiophenes / pharmacokinetics
• Thiophenes / therapeutic use
• Thrombin / antagonists & inhibitors
• Thrombophilia / drug therapy*
• Thrombosis / drug therapy
• Thrombosis / prevention & control*
• Warfarin / therapeutic use